Presentation is loading. Please wait.

Presentation is loading. Please wait.

Omega-3s vs Pure EPA in Clinical Practice

Similar presentations


Presentation on theme: "Omega-3s vs Pure EPA in Clinical Practice"— Presentation transcript:

1 Omega-3s vs Pure EPA in Clinical Practice

2 Rationale for the Use of Fish Oil

3 Primary and Secondary CVD Prevention Trials Evaluating Treatment of TGs

4 Rationale for the Use of Highly Purified EPA

5 REDUCE-IT Study Design

6 REDUCE-IT Primary and Secondary Endpoint Results

7 REDUCE-IT Prespecified Hierarchical Testing

8 REDUCE-IT CV Benefit of EPA Independent of LDL-C Levels

9 Ischemic Event Reduction With Icosapent Ethyl

10 Ischemic Event Reduction With Icosapent Ethyl Statistical Handling

11 REDUCE-IT Analysis Reduction of First and Subsequent Events

12 First and Total Events Over the Years

13 Primary Composite Endpoint Total Endpoint Events by Baseline TG Tertiles

14 REDUCE-IT Change in Biomarkers After 1 Year

15 Risk Differences With Icosapent Ethyl

16 Safety Results

17 REDUCE-IT Serious Bleeding

18 Medications Taken at Baseline

19 Membrane Stabilization

20 Effects of EPA on Plaque Progression

21 Prescription-Only Omega-3s vs Dietary Supplement Omega-3s

22 2018 Cholesterol Guidelines Secondary Prevention in Patients With Clinical ASCVD

23 Collaborative Care

24 Conclusion

25 Abbreviations

26 Abbreviations (cont)

27 Abbreviations (cont)


Download ppt "Omega-3s vs Pure EPA in Clinical Practice"

Similar presentations


Ads by Google